Abstract:Strategies to address the problem of poorly water-soluble drugs encompass the conversion of a crystalline drug into an amorphous form to promote its apparent solubility and dissolution. Co-amorphous systems (CAMs) incorporate low molecular mass molecules (co-formers), which are mixed with the drug to form one single phase [1 Blaabjerg LI, Lindenberg E, Rades T, et al. Influence of preparation pathway on the glass forming ability. Int J Pharm. 2017;521(1–2):232–239.[Crossref], [PubMed] , [Google Scholar],2 Dengale SJ, Grohganz H, Rades T, et al. Recent advances in co-amorphous drug formulations. Adv Drug Deliv Rev. 2016;100:116–125.[Crossref], [PubMed], [Web of Science ®] , [Google Scholar]]. The aim of this study is to understand the capability of different co-formers (amino, carboxylic and sulphonic acids), in the production of CAMs with olanzapine by ball milling, solvent evaporation and quench cooling.Mixtures (2 g) of olanzapine (OLZ) and each co-former [l-aspartate (ASP); l-tryptophan (TRY); l-arginine (ARG); l-proline (PRO); citric acid (CIT); tartaric acid (TAR); oxalic acid (OXA); saccharine (SAC); potassium acessulfame (ACE); cyclamic acid (CYC)] in 1:1 molar ratios were submitted to ball milling (BM), solvent evaporation (SE) and quench cooling (QC). CAMs were evaluated for the OLZ solubility increase, co-formability and storage stability over time, by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD) and Fourier-transform infra-red spectroscopy (FTIR).The BM technique presented the most promising results followed by QC and SE (Table 1), since more CAMs were produced. All the sulphonic acids (SAC, CYC and ACE) formed CAMs regardless of the technique used, presenting complete amorphization probably due to their higher ability to produce intermolecular interactions, like hydrogen-bonding, thus increasing the stability of CAMs (more than 8 weeks at 25 °C/11 and 53% RH). Conversely, amino acids were the least efficient in producing CAMs. Crystalline OLZ presented low solubility (40.1 mg/L) in water and a general increase in the solubility of the CAMs was observed. Carboxylic acids (TAR, CIT, OXA) achieved the biggest increase (up to 269 times, BM with TART) followed by sulphonic acids (up to 199 times, SE with SAC), unveiling the possibility of improved dissolution profiles and bioavailability. Discussion and conclusions: The study has shown the possibility of converting a crystalline drug into an amorphous entity, particularly when in presence of co-formers which stabilise the amorphous structures formed. In fact, with sulphonic acids, both SE and BM, achieved complete amorphization and successfully stabilised the CAMs obtained. Due to the noteworthy increase in solubility, resulting from co-amorphization, this technique is considered to be adequate to process active compounds with poor water solubility, such as OLZ.Table 1. Comparison of the of co-amorphization ability using different techniques and co-formers.

Co-amorphization of posaconazole using citric acid as an acidifier and a co-former for solubility improvement

Poly (amino acid)s as new co-formers in amorphous solid dispersion

Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous

Poly(vinylpyridine- co -vinylpyridine N -oxide) Excipients Mediate Rapid Dissolution and Sustained Supersaturation of Posaconazole Amorphous Solid Dispersions

Amino Acids As Co-Amorphous Excipients for Tackling the Poor Aqueous Solubility of Valsartan.

Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs

Co-formability, solubility enhancement and stability of olanzapine co-amorphous systems produced with different co-formers

Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study

Co-Amorphization of Acemetacin with Basic Amino Acids as Co-Formers for Solubility Improvement and Gastric Ulcer Mitigation

Selection of Bionic Co-former Improves the Dissolution of Neohesperidin via Co-amorphous Solid Dispersion with Naringin

Amorphous solid dispersions of carvedilol along with pH-modifiers improved pharmacokinetic properties under hypochlorhydoria

Water-mediated phase transformations of posaconazole: An intricate jungle of crystal forms

Enhancing Stability and Formulation Capability of Fungicides by Cocrystallization Through a Novel Multistep Slurry Conversion Process

Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability

Aggregation of Hydroxypropyl Methylcellulose Acetate Succinate under its Dissolving pH and the Impact on Drug Supersaturation.

Amphiphilic disodium glycyrrhizin as a co-former for ketoconazole co-amorphous systems: Biopharmaceutical properties and underlying molecular mechanisms

Generality of Enhancing the Dissolution Rates of Free Acid Amorphous Solid Dispersions by the Incorporation of Sodium Hydroxide

Chemistry and Ionization of HPMCAS Influences the Dissolution and Solution-Mediated Crystallization of Posaconazole Amorphous Solid Dispersions

"Felodipine-Indomethacin" Co-Amorphous Supersaturating Drug Delivery Systems: "Spring-Parachute" Process, Stability, in Vivo Bioavailability, and Underlying Molecular Mechanisms

Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization

Co-amorphization of atorvastatin by lisinopril as a co-former for solubility improvement